{"id":1551,"date":"2024-06-18T02:29:30","date_gmt":"2024-06-18T02:29:30","guid":{"rendered":"https:\/\/dornsife.usc.edu\/kuhn\/?page_id=1551"},"modified":"2024-07-30T15:24:23","modified_gmt":"2024-07-30T15:24:23","slug":"digital-health","status":"publish","type":"page","link":"https:\/\/dornsife.usc.edu\/kuhn\/digital-health\/","title":{"rendered":"Digital Health"},"content":{"rendered":"\n\n\n\n \n \n\n\n\n\n\n\n\n
\n\n \n \n
\n\n \n

Providing personalized and precision oncology requires an exact understanding of the cancer and the patient\u2019s overall health condition. While much of our work at CSI-Cancer is focused on the cancer, we have identified a series of technical solutions to address challenges in current clinical health assessments. We define those solutions as the Digital Health Companion as these solutions support the patient\u2019s journey.<\/p>\n

Our scientific discovery underpinning the Digital Health Companion pointed us to the need to objectively assess the patient\u2019s health performance status. This is currently done in the physician\u2019s office during the initial consultation when broadly speaking, the physician watches the patient as they move from the chair to the exam table. It is that movement together with patient interview questions that becomes the performance status score in the health chart to decide on fitness for specific treatments. To replace this subjective Physician assessment, we have developed a data-driven solution that provides an objective measure of the health performance status by utilizing 3D cameras at the clinic and movement trackers at home. This work was both published in the scientific literature and has received prominence at both public audiences, including a demonstration at the White House event South by South Lawn, and scientific audiences, including the opening plenary lecture at the largest annual cancer research conference, the American Association of Cancer Research. Through these efforts, we developed a path of building both the science and the implementation of clinical care for patients, which we call the Digital Health Companion.<\/p>\n

We have implemented Digital Health Companion technology to support several patient clinical trials to objectively assess human performance. Currently we have four clinical trials enrolling cancer patients undergoing therapy who are at risk of failing health due to both the drug therapy and their overall health performance \u2013 our goal is to both predict and prevent health failure and decipher the relationship between overall health and drug related challenges.<\/p>\n

These Digital Health Companion technologies will enable better outcomes for patients at a reduced cost to the healthcare system through digital biomarkers.<\/p>\n\n\n\n<\/div>\n\n\n <\/div><\/div>\n\n\n\n\n\n\t\n\n \n \n\n\n\n\n\n\n\n

\n\n \n
\n\n
\n
\n\n \n \n
\n\n \n

\n ATOM-HP\n <\/h2>\n\n\n<\/div>\n \n \n
\n\n \n

The\u00a0A<\/strong>nalytical\u00a0T<\/strong>ools to\u00a0O<\/strong>bjectively\u00a0M<\/strong>easure\u00a0H<\/strong>uman\u00a0P<\/strong>erformance (ATOM-HP) was a pilot project aimed at quantifying PS to complement the current clinical assessment. A more objective evaluation of PS was obtained by tracking routine activities with consumer-grade biometric sensors and cameras and translating them into quantitative performance measures. In addition, an app designed for daily patient symptom reporting from a cell phone was used to collect daily ratings of fatigue, appetite, physical activity, sleep disturbance, and body weight.<\/p>\n

ATOM-HP Primary Objectives:<\/strong><\/p>\n